Rockefeller Capital Management
BBOT

Rockefeller Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Rockefeller Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.62K Buy
1,000
+300
+43% +$2.5K ﹤0.01% 4115
2026
Q1 		$6.26K Hold
700
– – ﹤0.01% 4181
2025
Q4 		$8.76K Buy
+700
New +$8.48K ﹤0.01% 3856

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Rockefeller Capital Management's BBOT Position: Q2 2026 in Review

Rockefeller Capital Management increased its BridgeBio Oncology (BBOT) stake by 43% in Q2 2026, buying an estimated $2.5K and bringing the position to 1,000 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

Rockefeller Capital Management first reported a position in BBOT in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.76K in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Rockefeller Capital Management held 1,000 shares of BridgeBio Oncology worth $7.62K as of Q2 2026.
  • Rockefeller Capital Management bought 300 BridgeBio Oncology shares in Q2 2026, an estimated $2.5K.
  • BridgeBio Oncology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4115 holding.
  • Rockefeller Capital Management first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's BridgeBio Oncology position peaked at $8.76K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.